Core Viewpoint - The announcement from Valiant Biopharma-B (09887) indicates the successful administration of Opalizumab (PD-L1/4-1BB bispecific antibody LBL-024) to the first patient in a Phase Ib/II clinical trial for platinum-resistant ovarian cancer [1] Group 1 - The clinical trial is an open-label, multicenter Phase Ib/II study led by Professor Wu Lingying from the Cancer Hospital of the Chinese Academy of Medical Sciences [1] - The trial is being conducted simultaneously across multiple hospitals in China [1] - The objective of the trial is to evaluate the efficacy and safety of Opalizumab in combination with paclitaxel for patients with platinum-resistant ovarian cancer [1]

Core Viewpoint - The announcement by Weili Zhibo-B (09887) highlights the successful administration of Opalizumab (PD-L1/4-1BB bispecific antibody LBL-024) to the first patient in an ongoing Phase Ib/II clinical trial for the treatment of platinum-resistant ovarian cancer [1] Group 1 - The clinical trial is an open-label, multicenter Phase Ib/II study led by Professor Wu Lingying from the Chinese Academy of Medical Sciences Cancer Hospital [1] - The trial is being conducted simultaneously across multiple hospitals in China [1] - The objective of the trial is to evaluate the efficacy and safety of Opalizumab in combination with paclitaxel for patients with platinum-resistant ovarian cancer [1]

Core Viewpoint - The announcement highlights the successful administration of LBL-024, a PD-L1/4-1BB bispecific antibody, in the first patient of a Phase Ib/II clinical trial for platinum-resistant ovarian cancer [1] Group 1: Clinical Trial Details - The clinical trial is an open-label, multicenter Phase Ib/II study led by Professor Wu Lingying from the Cancer Hospital of the Chinese Academy of Medical Sciences [1] - The trial is being conducted simultaneously across multiple hospitals in China [1] - The objective of the trial is to evaluate the efficacy and safety of LBL-024 in combination with paclitaxel for patients with platinum-resistant ovarian cancer [1]

Nanjing Leads Biolabs Co., Ltd. 南 京 維 立志博生物科技股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 （於 中 華 人 民 共 和 國 成 立 的 股 份 有 限 公 司） （股 份 代 號：9887） 自願公告 LBL-024於鉑耐藥卵巢癌IB/II期試驗的首例患者用藥 本公告由南京 維 立志博生物科技股份有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，以 告 知 本 公 司 股 東 及 潛 在 投 資 者 有 關 本 公 司 的 最 新 業 務 發 展 情 況。 本 公 司 欣 然 宣 布，評 價 奧 帕 替 蘇 米 單 抗（PD-L1/4-1BB雙特異性抗體LBL-024）用 於治療鉑耐藥卵巢癌的Ib/II期 臨 床 研 究 首 例 患 者 已 成 功 用 藥。 關 於LBL-024 LBL-024是一種 ...

Core Viewpoint - The announcement from Valiant Biopharma-B (09887) highlights the successful administration of the first subject in the Phase I clinical trial of LBL-047, focusing on its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy [1] Group 1: Clinical Trial Details - The Phase I study is a randomized, double-blind, placebo-controlled, single ascending dose trial conducted in healthy adults and patients with systemic lupus erythematosus (SLE) [1] - The healthy volunteer segment is led by Professor Meng Xianmin from Shanghai Public Health Clinical Center, while the SLE segment is overseen by Professors Ye Shuang and Chen Sheng from Renji Hospital, affiliated with Shanghai Jiao Tong University School of Medicine [1] Group 2: Drug Mechanism and Potential - LBL-047 is a bispecific fusion protein composed of a humanized anti-BDCA2 antibody and a modified transmembrane activator and calcium-modulating cyclophilin ligand (TACI) extracellular domain [1] - The drug selectively eliminates plasmacytoid dendritic cells (pDC) to reduce type I interferon production and inhibits the B-cell activating factor (BAFF) and proliferation-inducing ligand (APRIL) signaling pathways, thereby blocking B-cell activation, differentiation, and antibody production [1] - This differentiated approach targets two major driving factors of autoimmune disease pathogenesis, indicating potential for treating various autoimmune indications [1] - LBL-047 has also been optimized to extend its half-life through Fc region modification [1]

Core Viewpoint - The announcement from Valiant Biopharma-B (09887) highlights the successful administration of the first subject in the Phase I clinical trial of LBL-047, focusing on its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy [1] Group 1: Clinical Trial Details - The Phase I study is a randomized, double-blind, placebo-controlled, single ascending dose trial conducted in healthy adults and patients with systemic lupus erythematosus (SLE) [1] - The trial aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy of LBL-047 [1] - The healthy volunteer segment is led by Professor Meng Xianmin from Shanghai Public Health Clinical Center, while the SLE segment is led by Professors Ye Shuang and Chen Sheng from Renji Hospital, affiliated with Shanghai Jiao Tong University School of Medicine [1] Group 2: Drug Mechanism and Potential - LBL-047 is a bispecific fusion protein composed of a humanized anti-BDCA2 antibody and a modified transmembrane activator and calcium-modulating cyclophilin ligand (TACI) extracellular domain [1] - The drug selectively eliminates plasmacytoid dendritic cells (pDCs) to reduce type I interferon production and inhibits the B-cell activating factor (BAFF) and proliferation-inducing ligand (APRIL) signaling pathways, thereby blocking B-cell activation, differentiation, and antibody production [1] - This differentiated approach targets two major driving factors of autoimmune disease pathogenesis, indicating potential for treating various autoimmune indications [1] - LBL-047 has also been optimized to extend its half-life through Fc region modification [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Nanjing Leads Biolabs Co., Ltd. 南 京 維 立志博生物科技股份有限公司 （於 中 華 人 民 共 和 國 成 立 的 股 份 有 限 公 司） （股 份 代 號：9887） 自願公告 LBL-047於I期試驗的首例受試者用藥 本公告由南京 維 立志博生物科技股份有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，以 告 知 本 公 司 股 東 及 潛 在 投 資 者 有 關 本 公 司 的 最 新 業 務 發 展 情 況。 本 公 司 欣 然 宣 布，評 價LBL-047安 全 性、耐 受 性、藥 代 動 力 學╱藥 效 動 力 學 及 初 步臨床有效性的I期 臨 床 研 究 首 例 受 試 者 已 成 功 用 藥。 該I期研究為在健康成年人和系統性紅斑狼瘡（SLE）患 者 中 進 行 ...

南 京 維 立志博生物科技股份有限公司 章 程 2025年12月 | 第一章 | 總 | | | | | | | | | | 則 | 2 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 第二章 | | | | | | | | | | | 經營宗旨和範圍 | 4 | | 第三章 | 股 | | | | | | | | | | 份 | 4 | | 第一節 | | | | 股份發行 | | | | | | | | 4 | | 第二節 | | | | 股份增減和回購 | | | | | | | | 8 | | 第三節 | | | | 股份轉讓 | | | | | | | | 10 | | 第四章 | | | | | | | | | | | 股東和股東會 | 13 | | 第一節 | | | 股 | 東 | | | | | | | | 13 | | 第二節 | | | | 股東會的一般規定 | | | | | | | | 20 | | 第三節 | | | | 股東會的召集 | | | | | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 Nanjing Leads Biolabs Co., Ltd. 南 京 維 立志博生物科技股份有限公司 （於 中 華 人 民 共 和 國 成 立 的 股 份 有 限 公 司） （股 份 代 號：9887） 於2025年12月17日舉行的 臨時股東會會議的 投票表決結果 南 京 維 立志博生物科技股份有限公司（「本公司」）董事會（「董事會」）宣 布，於2025 年12月17日舉行的本公司臨時股東會會議（「臨時股東會會議」）上，所 提 呈 載 於 臨時股東會會議通告（「臨時股東會會議通告」）的決議案已獲本公司股東以投 票 方 式 正 式 通 過。除 另 有 所 指 外，本 公 告 所 用 詞 彙 與 本 公 司 日 期 為2025年11月 28日的通函（「通 函」）所 界 定 者 具 有 相 同 涵 義。 臨 時 股 東 會 會 議 的 投 票 表 決 ...

Core Viewpoint - The company has submitted filing materials to the China Securities Regulatory Commission for the implementation of H-share full circulation, converting a total of 44.3916 million unlisted shares into H-shares, which represents approximately 22.32% of the company's total issued share capital of 199 million shares as of the announcement date [1] Group 1 - The company plans to convert 44.3916 million unlisted shares into H-shares [1] - The conversion will account for about 22.32% of the total issued share capital [1] - The filing was submitted to the China Securities Regulatory Commission on December 15, 2025 [1]